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Background: Infant colic, characterised by excessive crying/fussing for no apparent cause, affects up to 20% of
infants under three months of age and is a great burden to families, health professionals and the health system.
One promising approach to improving its management is the use of oral probiotics. The Baby Biotics trial aims to
determine whether the probiotic Lactobacillus reuteri DSM 17938 is effective in reducing crying in infants less than
three months old (<13.0 weeks) with infant colic when compared to placebo.
Methods/Design: Design: Double-blind, placebo-controlled randomised trial in Melbourne, Australia. Participants:
160 breast and formula fed infants less than three months old who present either to clinical or community services
and meet Wessel’s criteria of crying and/or fussing. Intervention: Oral once-daily Lactobacillus reuteri (1x108 cfu)
versus placebo for one month. Primary outcome: Infant crying/fussing time per 24 hours at one month. Secondary
outcomes: i) number of episodes of infant crying/fussing per 24 hours and ii) infant sleep duration per 24 hours (at
7, 14, 21, 28 days and 6 months); iii) maternal mental health scores, iv) family functioning scores, v) parent quality
adjusted life years scores, and vi) intervention cost-effectiveness (at one and six months); and vii) infant faecal
microbiota diversity, viii) infant faecal calprotectin levels and ix) Eschericia coli load (at one month only). Analysis:
Primary and secondary outcomes for the intervention versus control groups will be compared with t tests and non-
parametric tests for continuous data and chi squared tests for dichotomous data. Regression models will be used to
adjust for potential confounding factors. Intention-to-treat analysis will be applied.
Discussion: An effective, practical and acceptable intervention for infant colic would represent a major clinical
advance. Because our trial includes breast and formula-fed babies, our results should generalise to most babies with
colic. If cost-effective, the intervention’s simplicity is such that it could be widely taken up as a new standard of care
in the primary and secondary care sectors.
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The burden of infant colic
Infant colic, characterised by excessive crying/fussing for
no apparent cause, is common and distressing to fam-
ilies. Infant colic is defined clinically by Wessel’s criteria
of crying and/or fussing ≥3 hours/day for ≥3 days/week
for ≥3 weeks [1]. In research, the modified Wessel’s cri-
teria of crying and/or fussing ≥3 hours/day for ≥3 days/
week for one week is used for practicality and feasibility,
due to the natural course of infant colic symptoms
appearing by around three weeks, peaking at eight
weeks, and remitting beyond 12 weeks of a term infant’s
chronological age. Infant colic affects up to 20% of
infants under three months [2,3].
Infant colic poses a great burden to families, health
professionals and the health system. Early infant sleeping
and crying problems are the most common reason par-
ents seek health professional help in the first three
months of life, costing an estimated £65 million pounds
per annum in the UK in 2001 [4]. Infant colic has sig-
nificant adverse effects on maternal mental health and
family quality of life [5,6] and is a trigger for child abuse
[7,8]. Infants in whom crying persists beyond three
months are at risk of adverse outcomes in the school
years including anxiety, aggression, hyperactivity, allergy,
and sleep disorders [9,10], and at more than double the
risk of poor mental health in later years [11]. Families of
infants with colic are more dissatisfied with their daily
family functioning in later years [12].
After 50 years of research into infant colic, its aetiology
remains unclear and evidence-based management options
limited. Finding an effective management strategy for in-
fant colic could significantly reduce its associated morbid-
ities and improve the quality of life of many families.
Proposed aetiological factors for infant colic
Debate continues around whether infant colic represents
an extreme of the spectrum of normal crying, or a mani-
festation of underlying physiological or psychosocial fac-
tors. Perhaps, infant colic is best thought of as an
exacerbation of infant crying with the aggravation brought
about by either physiological factors within the infant, or
psychosocial issues with the mother and infant [13]. Pro-
posed psychosocial theories include difficult infant tem-
perament, immaturity in the infant’s ability to modulate
reactions to internal and external stimuli, inadequate
maternal-infant interaction and maternal anxiety [13].
Physiological theories are based on gastrointestinal fac-
tors, including gut dysmotility, excessive intragastrointest-
inal air, and visceral pain [14,15]. However, no study has
been able to definitively prove whether these are causal
factors of infant colic. Gastro-oesphageal reflux was trad-
itionally assumed to be a cause of infant distress, but sev-
eral recent clinical trials have demonstrated that it is anunlikely cause for persistent crying [16,17]. Food allergy is
perhaps the strongest factor identified so far in the causal
pathway to crying [18-22], with gut inflammation resulting
from allergy to cow’s milk protein assumed to be the
underlying mechanism. Faecal calprotectin, a gut inflam-
matory marker, has been identified to be higher in infants
with colic compared to those without in one study [23],
although another study did not confirm this finding
[24]. Another possible mechanism may be an alteration
of gut microbiota in infants with cow’s milk protein
allergy [25,26].
Recent research has focussed on the pathophysiological
role of gut microbiota in the exacerbation of infant crying.
This promising new hypothesis is currently generating
substantial research interest, with several studies confirm-
ing differences in gut microbiota between infants with and
without colic. One study indicated increased concentra-
tions of faecal Clostridium difficile in infants with colic
compared to controls [27], while two studies reported
increased Eschericia coli (E coli) concentrations and
reduced Lactobacillus species concentrations in infants
with colic compared to controls [28,29]. Another study
identified certain Lactobacillus strains to predominate in
infants with colic compared to controls [30], while a more
recent study suggested certain Bifidobacterium and Lacto-
bacillus species to be protective against crying [31]. These
findings suggest that while the microbiota are likely to be
different in infants with colic, it remains uncertain
whether these microbiota differences are the cause or re-
sult of the colic condition. Disturbances in gut microbiota
may lead to mechanical changes in the gut, such as gas
production and bloating and/or gut dysmotility [32,33],
which in turn lead to infant crying. The aetiology of infant
colic is likely multifactorial.
Current treatment options for infant colic
Four systematic reviews have evaluated the effectiveness
of interventions for infant colic [34-37]. The best evi-
dence supports the use of hypoallergenic or extensively
hydrolysed whey or casein-based formula in infants, and
instigating maternal elimination diets in breastfeeding
mothers, supporting the role of food allergy as a cause
of persistent infant crying. However, elimination of cow’s
milk from breastfeeding mothers is not always effective
and it is unclear which babies respond to hypoallergenic
diets and which do not. Other possible effective strat-
egies include improved parental responsiveness, reduced
stimulation and the use of sucrose. Ineffective strategies
include focused parental counselling, increased carrying,
use of car ride stimulators, soy milk and fibre enriched
diets. Proton-pump inhibitors for presumed gastrooeso-
phageal reflux disease are ineffective [17]. Simethicone, an
anti-foaming agent used to reduce intragastrointestinal
gas and bloating, is also ineffective [38,39]. Anticholinergic
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with significant adverse effects in infants [2,35]. Providing
families with support is effective in reducing caregiver
stress, but effects on crying are inconclusive [34]. There
are therefore no effective and feasible strategies that can
be easily implemented to help families with infants with
colic.
Use of probiotics and the potential role of Lactobacillus
reuteri in infant colic
One promising new approach to the management of in-
fant colic is the use of probiotics. Probiotics are live
microorganisms believed to confer health benefits and
are used widely in food products, including infant for-
mulae [40]. Probiotics colonise the bowel, competitively
inhibit other bacterial adhesion, stimulate host immune
responses to pathogens, suppress intestinal inflamma-
tion, increase mucus layers and strengthen mucosal
barriers [41-43]. Probiotics can modulate infant gut
microbiota and increase microbiota diversity [44-52]. A
recent study demonstrated specific Lactobacillus strains
were able to inhibit the growth of gas-producing coli-
forms isolated in infants with colic [32]. Probiotics and
prebiotics have also been shown to alter gastrointestinal
motility in newborns by stimulating gastric emptying
[33]. Animal studies have shown probiotics to change
pain perception mediated by the gut and inhibit gut
contractile activity in rats [53-59]. Another explan-
ation is that probiotics may reduce gut inflammation,
from whatever cause, in turn reducing associated in-
fant distress.
Four randomised controlled trials have examined the
therapeutic effects of probiotics in treating infant colic.
In 2007, Savino et al. reported a significant benefit in the
use of Lactobacillus reuteri (L reuteri) strain ATCC
55730 in the treatment of infant colic when compared
with simethicone (n = 83) [60]. This study was replicated
in 2010 using L reuteri strain DSM17938 as the inter-
vention and a placebo (n = 50), with similar promising
results [61]. Both studies involved only exclusively
breastfed infants whose mothers were all on cow’s milk-
free diets. Two other trials using different mixtures of
probiotics investigated their therapeutic effects on infant
colic (n = 9, n = 62) [52,62] and concluded there were no
significant effects on crying time.
The mixed results in the above studies mean that the
role of probiotics (including L reuteri) in the treatment
of infant colic remains uncertain. Moreover, the findings
may not necessarily be applicable to the general popula-
tion since in both the Savino et al. trials, the study popu-
lations were restricted to breastfed infants whose
mothers were on a cow’s milk-free diet (a select group
that is not representative of the general population). Fur-
thermore, there are methodological concerns regardingthe previous studies that require further investigation.
For example, the comparison group in the 2007 Savino
et al. study was simethicone rather than a placebo, which
meant that the interventions could not be blinded due
to differences in dosage and time of administration. The
other trials lacked sufficient power to detect differences
and used combinations of probiotics, which can contrib-
ute to varying results since probiotic bacteria are known
to have species specific effects [52,62]. In summary,
there is insufficient evidence to recommend the use of
probiotics in infant colic.
Aims and hypotheses
This double-blind, placebo-controlled randomised trial
aims to determine whether the probiotic L reuteri DSM
17938 benefits infants <3 months old (<13.0 weeks) with
colic by reducing daily duration of infant crying/fussing.
Secondary aims are whether there is reduced daily fre-
quency of episodes of infant crying/fussing, and improved
infant sleep, maternal mental health, and parent and fam-
ily functioning. We also aim to investigate changes in gut
microbiota, faecal calprotectin and E coli colonisation
which are all possibly implicated in the mechanism of dis-
ease, and finally to determine whether probiotic use
reduces healthcare costs in infant colic.
We hypothesise that, compared to the placebo (control)
group, the L reuteri (intervention) group will have lower
daily crying/fussing time per 24 hours at one month post
randomisation. We further hypothesise that the L reuteri
(intervention) group at 7, 14, 21, 28 days and 6 months
post randomisation will have:
 lower crying/fussing time per 24 hours,
 fewer crying/fussing episodes per 24 hours,
 longer sleep duration,
 higher scores on a standardised measure of maternal
mental health (one and six months),
 higher scores on a standardised measure of family
functioning (one and six months), and
 higher scores on a standardised measure of parent
quality adjusted life years (one and six months).
We also hypothesise that the intervention group com-
pared to the control group will have (at one month):
 more diverse gut microbiota,
 lower faecal calprotectin levels, and
 less E. coli colonisation, thereby suggesting a potential
pathophysiological mechanism in infant colic.
Finally, we hypothesise that the intervention will be
potentially cost-saving to the health care system by
diverting families away from more expensive manage-
ment such as overnight stays at mother-infant units.
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Study design, setting and participants
This is a phase III, double-blind, randomised placebo-
controlled trial drawing on clinical and community
based samples. The trial has been approved by the Royal
Children’s Hospital Human Research Ethics Committee
(HREC 30111).
Recruitment is from a range of services widely used by
and readily accessible to parents seeking medical advice
regarding their crying babies in Melbourne, Australia.
These comprise: the Royal Children’s Hospital Emer-
gency Department (RCH ED), the RCH Unsettled Babies
clinic (a tertiary referral-based clinic for assessment and
management of unsettled babies), Tweddle Child and
Family Health Centre (a mother-infant parenting centre),
two Maternal Child Health centres (universal nurse
health checks in the Boroondara and Moonee Valley dis-
tricts), and paediatricians at the RCH and in private
practices. Interested families can also directly contact
the study team to be involved.
A total sample of 160 infants less than three months
(13.0 weeks) old with infant colic is being recruited be-
tween August 2011 and August 2012. The expected total
duration of the study from the start of recruitment to
the last subject finishing the six month follow-up is
18 months. The treatment period is one month, with a
follow-up period of six months.
Inclusion criteria
Each infant must meet all of the following criteria to be
enrolled in this study:
1. Infant colic, i.e. crying or fussing ≥ 3 hours/day
for ≥ 3 days over seven days (as defined by the
modified Wessel’s criteria) by caregiver’s report at the
time of study commencement;
2. Less than three months (i.e. up to and excluding
13.0 weeks) old at the time of study
commencement;
3. Greater than 36 weeks gestation at birth; and
4. Birth weight of more than 2500 g.
Exclusion criteria
Infants meeting any of the following criteria are
excluded from the study:
1. Failure to thrive (weight gain < 100 grams/week
averaged from birth to the last recorded weight);
2. Major medical problems (eg. ill,
immunocompromised, major developmental or
genetic abnormality);
3. Taking solids, antibiotics or L reuteri and, if
breastfeeding, has mother taking L reuteri at the time
of study commencement;4. Cow’s milk protein allergy, defined as resolution of
crying after a paediatrician-recommended two
week trial of dairy-free diet in the infant, or in the
mother if breast-feeding, at the time of study
enrolment; and
5. Caregiver has insufficient English to understand
informed consent and complete questionnaires.
Randomisation
A block randomisation schedule to maintain balance be-
tween treatment arms has been prepared by an inde-
pendent statistician, not directly involved in the analysis
of the study results, from the Clinical Epidemiology and
Biostatistics Unit (CEBU) at the RCH and supplied to
Pharmacy who dispense the study product. Randomisa-
tion is stratified by method of infant feeding (breastfed
versus formula-fed) and age at the time of study com-
mencement (≤6 weeks versus >6 weeks, due to the nat-
ural crying peak occurring at around six weeks of age).
Infants on a mixture of both breast- and formula-
feeding are allocated to the formula-fed stratum. To
minimise potential biases, the study is double-blind
whereby treatment allocation is concealed from all study
investigators and participants.
Treatment arms, dosage and route of administration
The intervention is L reuteri DSM 17938 (0.2x108 cfu
per drop as five drops per day) in an oil suspension.
Under refrigeration, it is stable for 21 months at 2°C to
8°C (as documented by the manufacturer, BioGaia
AB, Stockholm, Sweden). The placebo is maltodex-
trose in the same oil suspension, identically packaged
and stored, and has the same appearance, colour and
taste as the intervention. Both intervention and pla-
cebo are labeled with only the randomisation number,
batch number, expiry date, and the statement “For
clinical trial use only”.
Carers administer five drops of study product orally to
each infant once daily for 28 days. The dose does not
need to be given at a fixed time each day, nor does it
need to be given with feeds. However, for compliance
and ease of administration, we recommend that families
give the dose with the same feed each day.
Outcome measures
Table 1 shows the primary and secondary outcome mea-
sures at different time points of the study. Table 2 shows
other information collected at different time points, in-
cluding family demographics, potential confounders,
physical assessments, and records of compliance and side
effects.
Study procedure details
Figure 1 and Figure 2 show details of study procedures.
Table 1 Outcome measures
Construct Timing (D=days/M=months) Measure Additional Information




■ Study diary A validated measure of infant crying/fussing/sleep/feeding and
records these behaviours in 5 minute epochs over 24 hours [65-
67]. At baseline parents record in the study diary for 24 hours. At
other time-points, the diary is filled in over 48 hours. This is to
account for daily variability in infant behaviour whilst taking into
account the potential burden to families from filling in the diary




■ ■ ■ ■ ■ Study diary
Number of episodes of
crying/fussing/day
■ ■ ■ ■ ■ ■ Study diary
Infant sleep duration
(mins/day)
■ ■ ■ ■ ■ ■ Study diary
Maternal mental health
scores




A 10-item validated questionnaire to screen for depression in the
post-partum setting, with higher scores indicating poorer mental
health [68]. Scores of ≥10 and ≥12 are validated to detect
postnatal depression in community and clinical settings,
respectively.
Parent functioning scores ■ ■ ■ PedsQL Family
Impact Subscale
A 5-item validated questionnaire to assess family functioning, with
higher scores indicating better family functioning [69].
Infant functioning scores ■ PedsQL Infant
Subscale
A 36-item validated questionnaire used to measure infant physical,
emotional, social and cognitive functioning [70].
Parent quality adjusted life
years scores
■ ■ ■ AQol-4R A 12-item validated questionnaire to assess the health economic
parent quality of life [71].






A molecular method to investigate the diversity within bacterial
communities, given as a diversity score, with higher scores
indicating more microbial diversity [72].
Infant faecal calprotectin
(mg/kg)
■ ■ ELISA An enzyme-linked immunosorbent assay to detect the presence of
calprotectin, a marker of gut inflammation [73].
Infant faecal E coli load
(cfu/ml)
■ ■ Quantitative PCR A molecular method to detect and measure the presence of
particular marker genes of E coli [74].
Table 2 Additional information collected
Measure Timing (D=days/M=months) Information Details




Family history of atopy. Antenatal / current probiotic / antibiotic use.
Smoking during pregnancy. Mode of delivery (caesarean versus vaginal).
Diary
questions
■ ■ ■ ■ ■ ■ Potential
confounders
Infant feeding method (breast versus formula). Mother’s intake of dairy,
probiotics, medications. Infant’s intake of dairy, probiotics, solids,
medications. Infant gastro-oesophageal reflux symptoms (measured by
the Infant Gastroesophageal Reflux Questionnaire Revised I-GERQ-R
[75,76], a validated measure of infant gastro-oesophageal reflux). Settling
techniques. Concurrent illnesses / immunisations.
Diary
questions
■ ■ ■ ■ ■ Compliance Number of days study drops missed over preceding week.
Diary
questions






Infants recruited through Maternal Child Health Nurses and Tweddle are
examined by the study paediatrician.
Weight ■ ■ Weight (kg, to
nearest gram)
Measured by the Wedderburn Infant Scale (Tanita Baby Scale Model
BD590) calibrated for the study.
Infant faecal L
reuteri (cfu/ml)
■ ■ Quantitative PCR A molecular method to detect and measure the presence of particular
marker genes of L reuteri, as a measure of compliance [77].
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Eligible families who present through the RCH ED are
identified in three ways: i) by the treating doctor, ii) by the
ED social worker, or iii) through the ED electronic data-
base. Eligible families who present through the RCH
Unsettled Babies Clinic are identified by their treating doc-
tors. Eligible families who present through the Boroondara
and Moonee Valley Maternal and Child Health Nurses and
Tweddle Child and Family Services are identified by their
nurses or intake worker. Potentially eligible families are re-
ferred to study team members, who call families or ap-
proach them in the ED or clinic if appropriate.Unsettled Babies 
Clinic
ED Social wED doctor
Approach family in ED /clinic to explain study 
Eligible (see text) 
Obtain: Give/mail 
1. Verbal/written consent 1. Parent i
2. Contact details 2. Baseline
3. Baby’s age (weeks) 3. Stool sp
4. Mode of feeding: breast or formula/mixed
Arrange Visit 1(home/RCH) in following week.  Medical reco
Telephone call to families (1 da
1. Reconfirm eligibility 4.  Remind carers to 
2. Confirm home or RCH visit 5.  Instruct carers to 
3. Confirm informed consent 6. Confirm mode of f
Day 1: SMS/telephone family to
Day 7, 14, and 21 SMS/telephone
1. Fill in diary 3. Report side effects
2. Continue study drops 4. Contact study team regarding 
Day 28 phone call to remin
1. Fill in diary and 1 month questionnaire 4. Report s
2. Stop study drops 5. Arrange
3. Collect stool sample
Final study v visit:
1. Collect diary and 1 month questionnaire, stool sample and 
2. Weigh infant
6 month questionnaire a
Visit 1 (baseline)
1.Researcher collects study bottle from pharmacy 5. Expla
according to randomisation and stratification 6. Weig
2. Confirm eligibility 7. Give 
3.Collect completed consent form and questionnaire 8. Colle
Figure 1 Study procedures.The study team establishes eligibility criteria. Infants
and breastfeeding mothers who are on a paediatrician-
recommended dairy-free diet, infants who are taking L
reuteri/solids/antibiotics, and breastfeeding mothers who
are taking L reuteri at the time of study enrolment are
reassessed for eligibility by telephone call after two
weeks. Eligible families are approached for consent. Each
family can choose to be visited at home or attend a visit
at RCH for the first study visit. Study researchers call
the families one day before the proposed study visit to
confirm the home or RCH visit. During this call, study
researchers reconfirm eligibility and consent, remindED databaseork
Telephone family to explain study 
Tweddle & Maternal 
Child Health 
Meets exclusion criteria        
Family not interested
family study pack containing:
nformation statement and consent form
 questionnaire
ecimen jar
rd check to confirm normal examination.  
y before Visit 1).
complete baseline questionnaire
collect stool sample
eeding: breast or formula/mixed
 start study drops 
 to remind family to: 
questions or intention to drop out of study
d family to:
ide effects
 final study visit
study bottle  
nd diary










































f ga b f ga b
a c a c
Collect faecal sample
Fill out Barr diary for 24 hours
Give daily dose of 5 drops L reuteri 
mixture
Give daily dose of 5 drops placebo mixture 
Telephone/SMS family
Fill out Barr diary for 48 hours
Day 1 f f
Figure 2 Perera diagram showing treatment and follow-up procedures.
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baseline questionnaire to complete them, and instruct
caregivers to collect a stool sample from their babies
and store it in a freezer. Study researchers also record
on the Clinical Record Form whether the babies are
breast- or bottle-fed.Visit one
During the visit, the researcher reconfirms eligibility,
asks the mother to complete the baseline questionnaire,
and reviews with the family in detail the study diary,
anticipated phone calls, the procedure of administering
the study product to the infant, and the anticipated
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weighs the baby, collects the stool sample and transports
it back to the RCH on ice in a portable cooler, and then
stores it in the laboratory −80°C freezer.
Study period Days 1 – 28
On days 1, 7, 14 and 21 the study team sends a mobile
text (SMS) message to families to remind families to fill
in the weekly diary. Study researchers call families on
day 28 to remind families to a) stop administration of
the study product; b) fill in the one month question-
naire; c) collect a stool sample; and d) make an appoint-
ment for the second (final) visit.
Visit two
During the second visit, the researcher weighs the infant,
and collects a) the study diary; b) the one month ques-
tionnaire; c) the study product bottle and d) a stool sam-
ple which is transported back to the RCH on ice in a
portable cooler, and then stored in the laboratory -80°C
freezer.
Six month follow-up
At six months, the families are sent a letter together
with a 24-hour study diary, a questionnaire and a reply-
paid envelope. Caregivers are asked to complete the
study diary and questionnaire, and return both in the
enclosed reply-paid envelope.
Compliance with the study product
Compliance is assessed by weighing of study bottles pre-
and post- dispensing, collection of faecal samples at the
end of the intervention period to assess for presence of
L reuteri in each infant’s stool, and weekly diary to rec-
ord administering of the product.
Data analysis
Estimation of sample size
We have selected a sample size of 160 to provide 80%
power to detect a minimum effect size of 0.5 standard
deviations, difference in the mean daily crying time be-
tween treatment groups with a significance level of
p < 0.05, allowing for a drop out rate of 20%. If the data
are substantially skewed, 80% power would be main-
tained to detect a minimum effect size of 0.525 [63,64].
In Savino’s trial [60], the percentage reduction in median
daily crying time at day 28 compared to baseline was
70% for the probiotic and 26% for simethicone, suggest-
ing substantive differences in this outcome are likely.
With a much larger sample size (double that of Savino’s
trial) in our study, we are confident we would also be
able to detect a smaller difference in daily crying time
reduction. Our sample size of 160 infants provides 80%
power to detect a minimum effect size of 0.85 standarddeviations, difference in the mean daily crying time be-
tween treatment groups within either the formula-fed or
breastfed babies, assuming 40% of infants in the sample
are exclusively breastfed.
We will be conducting an intention-to-treat analysis in
which participants are compared according to the group
to which they were randomly allocated regardless of par-
ticipants' compliance, crossover to other treatments or
withdrawal from the study. This approach preserves the
prognostic balance in the study arms achieved by
randomisation.
Baseline characteristics and study outcomes will be
described for each treatment group using means and
standard deviations for normally distributed continuous
outcomes, while medians and inter-quartile ranges will
be used for continuous outcomes that are skewed. Pro-
portions for categorical data will be given. All primary
and secondary outcomes for the intervention versus
control groups will be compared with t tests and non-
parametric tests for continuous data, and chi squared
tests for dichotomous data. The primary outcome is the
crying time/24 hours at day 28. We will additionally
consider a dichotomised indicator of treatment response
defined as a 50% reduction in crying time. Subgroup
analyses are intended a priori to examine treatment dif-
ferences amongst breastfed babies and those who are
formula-fed, and amongst infants with a family history
of atopy and those without.
Regression models will be used to estimate treatment
effect sizes, odds ratios and 95% confidence interval,
adjusting for potential confounding factors identified a
priori and measured at baseline. These include infant
age (≤6 weeks versus >6 weeks, taking into account the
natural course of infant colic symptomatology with the
peak of crying at six weeks), mode of birth delivery, ma-
ternal smoking, use of antibiotics or probiotics in infants
and breastfeeding mothers, maternal diet if breastfeed-
ing, maternal mental health scores, and known causes of
crying (e.g. fever, eczema, vaccination, vomiting, and
diarrhoea). Random effects regression models will be
used for further longitudinal analysis examining trends
in crying time within individual babies.Discussion
Infant colic is common, distressing, impacts adversely
on maternal mental health, and is a risk factor for
shaken baby syndrome. An effective, practical and ac-
ceptable intervention for infant colic would represent a
major clinical and public health advance. As our trial
will include breast and formula-fed babies, regardless of
maternal diet, our results can be generalised to most ba-
bies presenting with colic. If cost-effective, the simplicity
of the intervention is such that it could be widely taken
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ary care sectors.
With the boom of probiotic products appearing on the
market, the use of probiotics in the community is be-
coming more widespread. It is therefore important to
provide sufficient sound scientific evidence for its effect-
iveness in infant colic before it becomes incorporated
into regular use by the community, and avoid unneces-
sary consumption of costly products if the intervention
is not found to be effective.
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